---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-001158"
form_type: "8-K"
ticker: "PMN"
cik: "0001374339"
company_name: "ProMIS Neurosciences Inc."
filed_at: "2025-02-19T23:59:59+00:00"
generated_at: "2026-05-26T10:52:53.798478+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# ProMIS Neurosciences separates with COO Gavin Malenfant; position eliminated.

## Summary
- Gavin T. Malenfant separated as COO effective February 14, 2025.
- Company terminated the COO role and will not replace Mr. Malenfant.
- Severance benefits will be provided under a Separation Agreement referencing his employment contract.

## SEC filing metadata
- accession: 0001558370-25-001158
- form_type: 8-K
- ticker: PMN
- cik: 0001374339
- company_name: ProMIS Neurosciences Inc.
- filed_at: 2025-02-19T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1374339/000155837025001158/0001558370-25-001158-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1374339/000155837025001158/pmn-20250214x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-001158
- JSON: https://secwatch.observer/filing/0001558370-25-001158.json
- Plain text: https://secwatch.observer/filing/0001558370-25-001158.txt

## Key facts
- Executive change
  Gavin T. Malenfant departed as Chief Operating Officer at ProMIS Neurosciences Inc..
  - Action: separated
  - Role: Chief Operating Officer
  source text: On February 14, 2025, ProMIS Neurosciences Inc. (the “Company”) separated with Gavin T. Malenfant as Chief Operating Officer of the Company, effective as of February 14, 2025
  evidence_url: https://www.sec.gov/Archives/edgar/data/1374339/000155837025001158/0001558370-25-001158-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.